

International All Cap Q1 investment update

April 2025

Investment manager Alex Summers and investment specialist Thomas Hodges give an update on the ACWI ex US All Cap, EAFE Plus All Cap and Developed EAFE All Cap strategies covering Q1 2025.

Your capital is at risk. Past performance is not a guide to future returns.

Thomas Hodges (TH): Welcome to this quarterly update video covering the international all-cap strategy. My name is Tom Hodges. I'm an investment specialist on the strategy and today I'm joined by Alex Summers, an investment manager on the strategy.

We aren't exactly short of talking points this quarter, from tariffs, to defence spending, to decreasing expectations for US growth, Chinese stimulus, and even the announcement of a fiscal bazooka by the incoming German government, certainly been eventful. And international equities have performed very strongly over this period, outperforming their US counterparts. And in particular, it was European markets which were rallying particularly hard.

And what's largely driven that has been defence and banks. And these are areas which are traditionally associated with the value style of investment. And that marks the continuation of a long trend now of 'value's' outperformance of 'growth' in parts of the international markets. In terms of our own performance, we did underperform over the quarter. And that is largely due to the fact that we are underweight banks and we don't own any defence companies. So Alex, let's start there.

Alex Summers (AS): Yeah. So first and foremost, we are growth investors. And banks have not been traditionally a place where we've found a lot of growth and returns on capital have been quite poor. And so it's just not really been an area where we've looked deeply. That said, recently, we've increased our exposure to banks. We've invested in SEB and UBS, where we see sort of differentiated opportunities for growth within those companies. But we've not sort of chased the Southern European banks, which have re-rated significantly over the last few years, but aren't really growing in sort of a traditional sense.

TH: And you mentioned re-rating there. That's certainly something which can be applied to defence as well. It's largely been a rally driven by announcements as opposed to delivered results so far.

AS: Yeah, so we've looked at quite a few defence companies. One of the big challenges is even if you accept the vision of the governments that's been announced that there will be a lot more spending in the future, and you agree that's definitely going to happen, deciding which companies will benefit the most from that is still quite challenging.

You have local politics, which might determine where one product is manufactured or another, which manufacturer is able to do it. You also have big questions about what the future of warfare will look like and what type of equipment we might need, how much equipment we're going to need. And all of those have made it really difficult to, from a bottom-up perspective, build conviction around a particular idea. And as you mentioned, a lot of re-rating has already occurred in these companies, which may have taken away any potential upside from here.

TH: And turning to the companies that we do own in the portfolios, we've been talking a lot about the potential for a cyclical recovery in multiple different areas, whether it's industrials, whether it's healthcare, even parts of the semiconductor supply chain. We've started to see that come through recently.

AS: Yes, companies like Sartorius, their customers have been ordering a lot as they replace their own diminished inventories at this point. Companies like ASML and Tokyo Electron have had really positive guidance for the year forward. And companies like TSMC continue to grow sort of 30 per cent a year. and are really undemanding valuations, which we found really exciting.

TH: And these are all companies which can benefit from wider international optimism broadening out. And part of that optimism isn't just coming from Europe, it's also coming from China. And that's relevant for all our clients, whether ACWI ex US or in the developed world as well, because it does have an effect on global growth. What are your thoughts on Chinese stimulus?

AS: Yes. So China has been a really disappointing market for a number of years as the economy has really slowed down. And one of the big surprises has been that over the last six months there's been quite a lot of stimulus announced. Every month there's a new bit of stimulus that's being announced. And private capital and private entrepreneurs seem to be being embraced again, which wasn't the case a few years ago. And that was probably best symbolized by Xi Jinping's recent meeting with various technology entrepreneurs which is really exciting, and that's exciting for our domestic Chinese names that we own, but it's also exciting for some of the global companies which we own as well in the developed markets.

So if China starts growing again, it's still the world's second largest economy. If it can really get growth going again, that will drive demand for metals, which BHP produces. It could lead to more

industrial automation in China, which SMC would be a big part of. And so, we find that quite exciting.

TH: And I asked you about China because you are an Asian and emerging markets specialist in some ways. What are your thoughts on opportunities around the world with regard to Asia and emerging markets, but also elsewhere, particularly in the face of a changing economic environment?

AS: Yeah, so change always creates risks and opportunities, and the best companies and the strongest management teams will be able to navigate the risks and take advantage of the opportunities. In emerging markets, we're very used to strongmen leaders, tariffs, trade restrictions, currency flow restrictions at this point. But we still find a number of companies which have very successfully navigated those and grown globally.

If you take TSMC, nobody thought 10 years ago that they would be successfully investing in US manufacturing capacity. And they've managed to do that and do that very profitably. And, you know, whether it's emerging markets or developed markets, these companies and management teams will act the same way and the best ones will thrive through this change.

TH: And we've taken up the opportunity to add three new holdings over the quarter. What companies did we purchase?

AS: Yeah, so as I mentioned earlier, we invested in UBS, which is a bank with a really dominant global private wealth business, which we find very interesting. Spirax, a global engineering company, and then Roche, which is really a global leader in diagnostics and pharmaceuticals.

TH: And I think those three companies really hit on what we've been investing in more broadly over the past year or so. That's companies which have underappreciated growth. And that's a real theme in the quarterly letter in our sort of ingredients for outperformance going forward. It's growth which can accelerate, but it's growth which isn't quite expected yet. Some of those companies, particularly Spirax and Roche, have had a weaker period over the past couple of years, particularly in the wake of COVID. So, what we're really looking for there is an acceleration in growth, but from a low starting multiple giving us the potential to benefit from both a growth return, but also a valuation re-rating.

And I think that brings us sort of neatly to sort of summarise really. We've underperformed over the quarter, ostensibly due to not owning the banks and defence companies which have rallied strongly in Europe.

But we think there's real opportunities for a growth acceleration across the portfolio. And that could be through a number of different areas, whether industrials, whether healthcare, whether semiconductor-related companies.

We've added three new holdings and they all fit what we're sort of viewing as the way to outperform going forward. That's focusing on growth, it's thinking differently, taking advantage of price dislocations. and also thinking long-term companies which can grow over the long term. So, we're feeling decidedly optimistic even in the face of a turbulent investment environment. And with that, thank you very much.

International All Cap (including ACWI ex US All Cap, EAFE Plus All Cap and Developed EAFE All Cap strategies)

Annual past performance to 31 March each year (net%)

	2021	2022	2023	2024	2025
ACWI ex US All Cap Composite	66.6	-16.4	-7.9	3.9	0.5
MSCI ACWI ex US Index	50.0	-1.0	-4.6	13.8	6.6
EAFE Plus All Cap Composite	60.7	-15.6	-6.4	2.4	-0.1
Developed EAFE All Cap Composite	61.5	-13.9	-7.4	2.3	-1.4
MSCI EAFE Index	45.2	1.6	-0.9	15.9	5.4

Annualised returns to 31 March 2025 (net%)

	1 year	5 years	10 years
ACWI ex US All Cap Composite	0.5	6.0	4.2
MSCI ACWI ex US Index	6.6	11.5	5.5
EAFE Plus All Cap Composite	-0.1	5.3	3.7
Developed EAFE All Cap Composite	-1.4	5.4	3.7
MSCI EAFE Index	5.4	12.3	5.9

The International All Cap Strategy comprises three distinct variants. Overall, the variants are broadly similar, with the key difference being the degree of exposure to emerging markets listed holdings.

Source: Revolution, MSCI. US dollars. Returns have been calculated by reducing the gross return by the highest annual management fee for the composite. 1 year figures are not annualised.

Past performance is not a guide to future returns.

Legal notice: MSCI makes no express or implied warranties or representations and shall have no liability whatsoever with respect to any MSCI data contained herein. The MSCI data may not be further redistributed or used as a basis for other indexes or any securities or financial products. This report is not approved, endorsed, reviewed or produced by MSCI. None of the MSCI data is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such.

Risk factors

This communication was produced and approved in April 2025 and has not been updated subsequently. It represents views held at the time and may not reflect current thinking.

The views expressed should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

This communication contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act ('FinSA') and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated.

The images used in this communication are for illustrative purposes only.

Important information

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Financial intermediaries

This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Europe

Baillie Gifford Investment Management (Europe) Ltd (BGE) is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. BGE also has regulatory permissions to perform Individual Portfolio Management activities. BGE provides investment management and advisory services to European (excluding UK) segregated clients. BGE has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. BGE is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited ('MUBGAM') is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited.

MUBGAM is authorised and regulated by the Financial Conduct Authority.

Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a "wholesale client" within the meaning of section 761G of the Corporations Act 2001 (Cth) ("Corporations Act"). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this material be made available to a "retail client" within the meaning of section 761G of the Corporations Act.

This material contains general information only. It does not take into account any person's objectives, financial situation or needs.

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited ('BGE') relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Israel

Baillie Gifford Overseas Limited is not licensed under Israel's Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755-1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Singapore

Baillie Gifford Asia (Singapore) Private Limited is wholly owned by Baillie Gifford Overseas Limited and is regulated by the Monetary Authority of Singapore as a holder of a capital markets services licence to conduct fund management activities for institutional investors and accredited investors in Singapore. Baillie Gifford Overseas Limited, as a foreign related corporation of Baillie Gifford Asia(Singapore) Private Limited, has entered into a cross-border business arrangement with Baillie Gifford Asia (Singapore) Private Limited, and shall be relying upon the exemption under regulation 4 of the Securities and Futures (Exemption for Cross-Border Arrangements) (Foreign Related Corporations) Regulations 2021 which enables both Baillie Gifford Overseas Limited and Baillie Gifford Asia (Singapore) Private Limited to market the full range of segregated mandate services to institutional investors and accredited investors in Singapore.